Lv1
90 积分 2023-08-04 加入
Data from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
3天前
已关闭
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
17天前
已完结
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
1个月前
已完结
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
1个月前
已完结
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
2个月前
已完结
Prognostic impact of HER‐2/neu expression on squamous head and neck carcinomas
2个月前
已关闭
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
2个月前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
2个月前
已完结
Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study
2个月前
已完结
Translational Insights and Overall Survival in the U31402-A-U102 Study of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC
5个月前
已完结
皖公网安备34019202002308
